# Andreas Jurgeit

> Andreas Jurgeit is a Series A investor at Gimv (Zürich) backing Health Care and Biotechnology. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Gimv](https://shizune.co/investors/profile/gimv)
- Location: Zürich, Switzerland
- Total investments: 5
- Last investment: Jan 2026
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://ch.linkedin.com/in/andreasjurgeit

Andreas Jurgeit is a Series A investor at Gimv in Zürich focused on Health Care and Biotechnology. Andreas Jurgeit is the Partner at Gimv. Andreas attended the University of Zürich.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 60% |
| Biotechnology | 3 | 60% |
| Pharmaceutical | 2 | 40% |
| Therapeutics | 1 | 20% |
| Health Diagnostics | 1 | 20% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Series B | 2 | 40% |
| Series C | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 40% |
| Germany | 1 | 20% |
| Switzerland | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Exciva | exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been formulated for developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using suchcompositions, enabling the healthcare industry to access their program for rescuing and reusing approved drugs for new indications and new uses. | $62.2M | Series B | Jan 20, 2026 |  |
| ImmunOs Therapeutics | ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease. | $11M | Series C | Sep 17, 2024 |  |
| Mediar Therapeutics | Mediar Therapeutics is a biotechnology company that develops antibody-based medicines and biologic therapies to address cancer, autoimmune diseases, and other serious health conditions. Its research platform focuses on engineering multi-specific antibodies and modular biologics that can engage multiple biological targets or pathways simultaneously,enabling precise modulation of immune responses. The company’s pipeline includes therapeutic candidates designed to activate or inhibit specific immune functions, with the goal of improving clinical outcomes in oncology and immune-mediated disorders. Mediar Therapeutics also works on scalable manufacturing processes and collaborates with scientific partners to advance its biologics from discovery through clinical development. Its approach integrates protein engineering, immunology, and translational research to create biologic medicines that address complex disease mechanisms. The company continues to refine its technology and expand its therapeutic programs to support future clinical and regulatory progress. | $85M | Series A | Mar 15, 2023 |  |
| ImmunOs Therapeutics | ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease. | $72.9M | Series B | Jun 07, 2022 |  |
| Indi Molecular | Indi Molecular is an emerging life sciences company that is developing a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. PCCs were created in collaboration with the California Institute of Technology using “click chemistry,” a synthetic process that allows scientists topermanently join (“click”) together molecular components with remarkable precision and stability. PCCs offer the promise of improved selectivity, superior binding affinity, fully synthetic composition and a vastly low molecular weight compared to monoclonal antibodies, the current standard for identifying biomarkers in most diagnostics platforms – and in many therapeutic uses.The company launched as a spinout from its parent company Integrated Diagnostics (Indi) in 2013 with a $1.5 million seed round led by InterWest Partners together with several angel investors. | $11.5M | Series A | Jun 29, 2017 |  |

5 of 5 investments shown.

## Co-investors
- [Mission BioCapital](https://shizune.co/investors/profile/bioinnovation-capital) — VC Fund, 3 deals together
- [Pfizer Venture Investments](https://shizune.co/investors/profile/pfizer-venture-investments) — VC Fund, 3 deals together
- [BioMedPartners](https://shizune.co/investors/profile/biomedpartners) — VC Fund, 2 deals together
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 2 deals together
- [Asset Management Ventures (AMV)](https://shizune.co/investors/profile/asset-management-ventures) — VC Fund, 1 deal together
- [Bristol-Myers Squibb](https://shizune.co/investors/profile/bristol-myers-squibb) — VC Fund, 1 deal together

## About Gimv

VC Fund · Antwerpen, Belgium

Gimv is a European investment company with over three decades of experience in private equity and venture capital.Gimv is listed on NYSE Euronext Brussels. Gimv currently manages around 1.8 billion EUR (including third party funds) of investments in 85 portfolio companies, which jointly realise a turnover of more than EUR 6 billion and employover 28,000 professionals.As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial and innovative companies with high-growth potential and supports them in their transformation into market leaders. Gimv’s four investment platforms are: Consumer 2020, Health & Care, Smart Industries and Sustainable Cities. Each of these platforms works with a skilled and dedicated team across Gimv’s home markets of the Benelux, France and Germany and can count on an extended international network of experts.More information on Gimv can be found on [www.gimv.com].

5 contacts available at Gimv.

| Name | Title | Profile |
| --- | --- | --- |
| Andreas Jurgeit | Partner | https://shizune.co/investors/profile/andreas-jurgeit |
| Anne Caron | Partner | https://shizune.co/investors/profile/anne-caron |
| Arie Hooimeijer | Partner | https://shizune.co/investors/profile/arie-hooimeijer |
| Bram Vanparys | Partner | https://shizune.co/investors/profile/bram-vanparys |
| Clemence Robles | Principal | https://shizune.co/investors/profile/clemence-robles |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Andreas Jurgeit invest in?

Andreas Jurgeit invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Andreas Jurgeit last invest?

The most recent investment recorded for Andreas Jurgeit closed in Jan 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co